NEW ORLEANS, LA—Sodium-glucose cotransporter 2 (SGLT2) inhibition does not seem to be a solution to the problem of arrhythmia ...

Background: Observational studies have suggested that sodium-glucose cotransporter 2 inhibitors (SGLT2i) are associated with a lower risk of atrial fibrillation (AF) recurrence after catheter ablation ...

Competing trials are under way that may show that the benefits of SGLT2 inhibitors in heart failure are a class effect. Sodium glucose cotransporter 2 (SGLT2) inhibitors, first approved to treat type ...

Adding an investigational nonsteroidal mineralocorticoid receptor antagonist (MRA) to an SGLT2 inhibitor led to a superior ...

Bristol-Myers Squibb and AstraZeneca announced positive results from a Phase 3 study of dapagliflozin as add-on therapy to metformin for the treatment of type 2 diabetes. This 24-week, randomized, ...

New findings show reduced hospitalizations for a wide group of patients with heart failure. For high-risk patients with reduced ejection fraction, the drug appears to cut deaths, but more studies will ...

Sodium-glucose co-transporter 2 (SGLT2) inhibitors, initially developed to treat type 2 diabetes, have significant heart- and ...

Please provide your email address to receive an email when new articles are posted on . Compared with placebo, dapagliflozin reduced risk for ventricular arrhythmias, cardiac arrest and sudden death, ...

AstraZeneca (($AZN)) announced an update on their ongoing clinical study. Study Overview: The OPTIMISE-CKD CEE study, officially titled ‘A ...

Please provide your email address to receive an email when new articles are posted on . Dapagliflozin did not improve diuretic efficiency for patients hospitalized with acute HF. It did, however, ...

Dapagliflozin improves a range of cardiovascular and renal outcomes in patients with type 2 diabetes without interacting adversely with other guideline-recommended medications, an analysis of ...

Credit: Shutterstock. Dapagliflozin, an oral SGLT2 inhibitor, decreased the risk of progression of focal segmental glomerulosclerosis compared with placebo, a subgroup analysis of the DAPA-CKD trial ...